Toxicity of the topoisomerase II inhibitors

Author: Seiter Karen  

Publisher: Informa Healthcare

ISSN: 1474-0338

Source: Expert Opinion on Drug Safety, Vol.4, Iss.2, 2005-03, pp. : 219-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Topoisomerase II inhibitors represent a broad class of antineoplastic agents with a wide spectrum of activity against malignancies. Topoi-somerase II inhibitors include the anthracyclines, mitoxantrone and epipodophyllotoxins. Short-term toxicity includes myelosuppression and gastrointestinal toxicity. Long-term survivors are at risk of cardiac toxicity and secondary leukaemia. This article discusses these toxicities in detail, including administration of these agents to patients with hepatic and/or renal insuffi-ciency, and the need for dose adjustments in selected patient populations.